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Abstract
The high incidence of diseases that affect the posterior segment of the eye (PSE) - here intended as composed 
by sclera, choroid and retina-prompts for establishing effective and well tolerated therapies. Topical application 
(instillation of drops) and systemic assumption remain the most widespread drug administration routes. However, 
the drug achieved levels are not therapeutically sufficient therapeutic, since in the first case the drug is mainly washed 
away by different pathways (aqueous humor, systemic adsorption, tears) and in the second reaches the PSE target in 
a minimal fraction. Intravitreal injections and biodegradable episcleral implants have emerged in the last decades as 
alternative, more effective, administration routes. Whilst these techniques already offer significant improvements, 
much space is still open to research. The difficulty in delivering drugs to the PSE via the intravitreal (IV) or episcleral 
(EP) route resides in the several physical and dynamical barriers-including blood retinal barrier, clearance from 
choriocapillaries and lymphatics-which hinder the passage of the drug molecules. In combination, and in support of 
clinical experiments, mathematical and computational methods can be used to simulate drug concentration levels in 
the tissues upon IV or EP administration. In this respect, this short review gives an update of the most recent (from 
year 2000 to present time) developments on mathematical models for drug delivery to the PSE. We specifically focus 
our attention on physiological modeling works that include spatial dependency. Our review work is organized in short 
sections accompanied by detailed tables. We discuss descriptions of the PSE morphology, considering “anatomically 
accurate” as well as reduced models and we analyze the biophysical phenomena included in the examined models. 
We present the numerical techniques adopted to solve the resulting systems of partial differential equations and 
we deal with the delicate issue of parameter choice and validation of the results. Eventually, we examine the main 
results and scientific achievements of the considered models. Our conclusions point out the absence of a “standard 
mathematical model” and highlight a significant scattering of the results obtained from the different authors.
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Abbreviations
ASE: Anterior segment of the eye; BCs: Boundary conditions; EP: Episcleral; FEM: Finite element method; 
IOP: Intraocular pressure; IV: Intravitreal; NS: Navier stokes equations; PSE: Posterior segment of the eye; 
RPE: Retinal pigmented epithelium
Introduction
The unique anatomy and physiology of the eye makes 
drug delivery to the PSE - here intended as composed by 
sclera, choroid and retina - a highly challenging task [1]. 
In the past, drugs targeting the PSE were administered 
for the most part via topical or systemic routes, but severe 
limitations and inefficiency sources were associated with 
these therapeutic approaches. Intravitreal injections and 
(juxta-) episcleral implants have more recently emerged 
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Table 1: Geometrical descriptions adopted in 3D physiological models of drug delivery to the PSE.
Reference Year Dimension
& species
Anatomical structures Boundary conditions on external surfaces Interface 
conditions
[16] IV implant 2005 3D rabbit lens, vitreous, hyaloid 
surface, lumped 
posterior membrane 
(combined retina-
choroid-sclera)
null drug concentration at the outer boundary 
of the lumped posterior membrane to model 
choriocapillary clearance, prescribed drug 
flux at the hyaloid membrane to represent 
drug clearance to the anterior region, drug 
mass flux on the surface of the implant 
continuity of drug 
concentration at 
vitreous/posterior 
membrane
[21] IV 
injection, 
IV implant
2005 3D rabbit anterior (posterior 
and anterior chamber, 
iris, ciliary processes, 
hyaloid membrane, 
Schlemm’s canal, 
cornea, lens) and 
posterior (vitreous, 
retina-choroid, sclera) 
segments of the eye
given aqueous flux from ciliary processes, 
retina/choroid, aqueous Schlemm's canal; 
zero drug concentration at the outer 
boundary of the posterior membrane to 
model choriocapillary clearance, null flux at 
the Schlemm's canal and for symmetry at 
iris, lens and cornea
continuity 
condition of drug 
concentration
[18] periocular/
IV inj
2007 1D mouse, 
human
periocular muscles/
connective tissue, 
episcleral potential 
space, sclera, choroid, 
retina
zero-flux condition at the external boundary 
of periocular tissues; zero drug concentration 
at the retina/vitreous boundary (for periocular 
injection) and prescribed concentration at the 
retina/vitreous boundary (for IV injection)
porous jump 
across membranes 
with partition 
coefficient
[13] systemic, 
episcleral
2008 3D human vitreous, retina, choroid/
sclera
no flux of aqueous and drug through the 
lens; fluid pressure equal to IOP at hyaloid 
and to episcleral veins pressure at sclera, 
imposed drug outward flux at hyaloid and 
sclera 
continuity of flow 
velocity and drug 
flux/concentration
[15] IV 
injection
2012 3D human, 
monkey, 
rabbit
vitreous, retina, choroid, 
sclera, lens, cornea, 
hyaloid, iris, ciliary body, 
Schlemm’s canal
given fluid inlet on the ciliary body, given 
pressure at the trabecular meshwork, 
sclera and cornea; given drug flux or drug 
concentration at the different outer surfaces, 
according to the specific considered delivery 
route
porous jump 
across membranes
[14] 
juxtascleral
2012 2D human choroid, sclera impermeable conditions at sclera/cornea 
and sclera/optic nerve interfaces, blood inlet 
at the optic nerve/choroid interface; porous 
jump at the internal surface of the choroid
no slip condition 
for velocity, 
continuous drug 
conc and flux 
[17] IV 
injection, 
episcleral, 
systemic
2014 3D human
modified 
from [13]
vitreous, retina, choroid, 
sclera
null fluid flux at the lens, fluid pressure equal 
to episcleral pressure at sclera, IOP pressure 
at hyaloid; prescribed drug loss at the ASE 
and at sclera surface, null drug flux at hyris/
lens
[19] episcleral 2014 3D human vitreous, retina, choroid, 
sclera
no slip conditions for flow at the external 
boundaries, except for inlet/outlet arteries 
and veins
porous jump 
across membranes 
with partition 
coefficient
[12] IV 
injection, 
episcleral, 
systemic (oral)
2014 3D human 
modified 
from [13]
vitreous, retina, choroid, 
sclera
fluid pressure equal to IOP at hyaloid 
membrane and to episcleral veins pressure 
at sclera; imposed drug outward flux 
at hyaloid, drug filtration at sclera, no 
permeation of aqueous humor and drug 
through the lens
[20] episcleral 2016 1D human vitreous, retina (tissue + 
blood), choroid, sclera
no flux from the vitreous; prescribed drug 
concentration at the sclera boundary
porous jump 
across membranes 
with partition 
coefficient
[22] 2016 3D human vitreous, retina prescribed fluid pressure at the boundaries 
and zero normal component;
zero flux at the vitreous boundary, jump 
conditions at the retinal boundary
fluid pressure 
continuity; porous 
jump across 
membranes
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important tools of analysis. Previous reviews specifically 
focusing on mathematical modeling of drug delivery to 
the PSE can be found in [4,5]. We refer to [2,6-9] for up-
to-date, comprehensive, reviews on physiological and 
clinical aspects of this topic.
The present short review gives an update of the 
most recent (from year 2000 on) developments on 
mathematical modeling of drug delivery to the PSE. 
We specifically focus our attention on physiological 
modeling works that include spatial dependency in the 
interested domains. This choice stems from the above 
observations about the inhomogeneous distribution of 
drug in the complex PSE structures, which definitely 
prompts for including spatial dependency in the models. 
We do not include mathematical models tailored to 
study drug distribution in the sole vitreous, for which a 
specific and relatively vast literature exists, see [10,11]. 
In our analysis, we have identified 11 papers which 
as alternative routes to achieve sustained therapeutic 
drug levels [2]. The penetration rate of a certain drug 
through these latter routes is influenced by its solubility, 
hydro/lipophilicity, charge, degree of ionization and 
molecular size [3]. Furthermore, drug concentration 
in the PSE tissues is not homogeneous but distributes 
in a complex way according to several concurrent 
biophysical phenomena as convection, diffusion, losses 
through anterior and posterior pathways, clearance 
mechanisms through blood and lymphatic vessels and 
degradation processes (see also Table 1 of [4]. It has also 
been observed [4] that only a weak correlation exists 
between the actual local drug concentration in the PSE, 
which determines the pharmacological response, and the 
mean concentration values that experiments can monitor 
in the more accessible aqueous chamber and vitreous 
body under in vivo conditions. In this perspective, 
mathematical and computational models can offer 
Table 2: Biophysical phenomena represented in 3D physiological models of drug delivery to the PSE.
Reference Drug 
diffusion
Drug convection Drug clearance Drug metabolism/
binding
RPE pumping Flow filtration
[16] all structures all structures none absent absent Darcy in vitreous 
and posterior 
membrane
[21] all structures all structures none absent implicit in 
permeability
NS in vitreous and 
aqueous
[18] all structures neglected 
(convection rate 
at least 20-fold 
lower than the 
rate of diffusion)
reaction term in 
choroid
reaction term (only in 
periocular tissue and 
choroid)
absent none
[13] all structures all structures clearance from 
choroid
absent fictitious 
convection in 
retina
Darcy in all layers
[15] all structures all structures parametric study 
on clearance 
from the ASE
absent absent NS in aqueous, 
Darcy elsewhere
[4] all structures only in choroid Periocular 
clearance 
modeled as 
decaying 
coefficient in the 
source
absent absent Darcy-Brinkman in 
all layers
[17] sclera, 
choroid, 
retina, 
vitreous
vitreous 
(neglected 
elsewhere)
clearance from 
choroid 
loss/degradation in 
retina and choroid
fictitious 
convection in 
retina 
Darcy in all layers
[19] all structures only in choroid none absent kinetic flux eq. 
retina/choroid
NS in choroid
[12] all structures all structures clearance from 
choroid
absent fictitious 
convection in 
retina
Darcy in all layers
[20] all structures all structures clearance from 
choroid and 
retinal vessel
reaction term fictitious 
convection in 
retina
Darcy in all layers
[22] all structures all structures choroid as perfect 
sink (boundary 
condition)
absent permeability 
coefficient at the 
retina/choroid 
boundary
Darcy in all 
structures
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main results and scientific achievements of the models. 
Eventually, in Sect. 6 we draw the conclusions.
Geometrical Modeling
Morphometric information on the PSE geometry 
has been traditionally obtained from dissection of 
specimina and, more recently, from digital imaging, both 
in animals and humans. In establishing a geometrical 
model for the PSE, important issues must be faced: 
i) which are the relevant anatomical structures to 
consider as mathematical domains of the model? ii) 
What are anatomically correct measures of the included 
volumes? (for example, the volume of the vitreous 
fulfill the above described criteria, and whose content is 
synthetically reviewed in table 1, table 2 and table 3. Each 
table is focused on a particular aspect of mathematical 
modeling of drug delivery to the PSE: representation of 
the PSE geometry, modeling of the relevant biophysical 
phenomena and discretization techniques adopted 
to obtain the numerical solution of the model on a 
computer.
We organize the review as follows. In Sect. 2, we analyze 
and compare the geometrical modelling choices; in Sect. 
3, we present the biophysical phenomena included in the 
models; in Sect. 4, we deal with the numerical techniques 
adopted to solve the models, and in Sect. 5 we discuss the 
Table 3: Details of the considered molecule and dose and of the numerical approaches considered in 3D physiological models of 
drug delivery to the PSE.
Reference Molecule Drug dosage/source Numerical 
approach 
Estimated coefficients
[16] Gd-DTPA (0.96 
kDa hydrophilic)
from in vitro release curves FEMs (FEMLab) diffusion coefficient in the posterior 
membrane fitted from in vivo 
models and MRI data
[21] fluoroscein, 
range of low-
to-high weight 
molecules
IV bolus injection: initial uniform 
concentration of drug throughout 
the hemi-spherical injection volume; 
implant: prescribed delivery rate
FEMs
[18] fluorescent 
protein (GFP)
prescribed constant drug 
concentration in the epiocular space
finite differences molucule diffusivities in sclera 
computed from Stokes-Einstein 
eq.; molecule diffusivities in the 
other layers estimated from scleral 
diffusivity and relative extracellular 
fractions 
[13] fluoroscein prescribed constant concentration at 
the sclera surface
FEMs mass transfer coefficient at the 
scleral surface and choriocapillary 
clearance rate from best fit between 
model predicted concentration of 
the vitreous and experiments
[15] fluoroscein, 
sucrose
prescribed initial drug concentration 
in the spherical injected bolus; 
different positions for injection
finite volumes 
(FLUENT)
hydraulic resistance of the trabecular 
meshwork adjusted until the desired 
IOP is obtained; diffusivities for the 
dextran polymers calculated via 
Stokes-Einstein equation
[14] anecortave 
acetate (0.39 
kDa)
exponential decay of drug 
concentration located in the 
episcleral depot point
finite volumes 
(FLUENT)
surface porosity of the sclera from 
TEM images
[17] fluoroscein, IgG1 
Fab(49 KDa, 
anti-VEGF)
prescribed exponential decay at the 
sclera boundary
FEMs sensitivity study on the mass 
transfer coefficient of igG1 Fab at 
the sclera external boundary 
[19] 1 kDa 
unspecified drug
prescribed drug initial condition in the 
patch
FEMs 
(COMSOL)
as in [13]
[12] fluoroscein systemic: given drug concentration 
in the choriocapillaries; IV inj: given 
drug concentration in the bolus
FEMs 
(COMSOL)
[20] low-weigth 
molecule
prescribed exponential decay FEMs
[22] small molecules 
(dexamethasone)
drug release from an implant 
located into the vitreous modeled 
via a diffusion equation for drug 
concentration and molecular weight
FEMs 
(COMSOL)
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the biophysical phenomena included in the considered 
mathematical models. All the models include diffusion 
mechanisms for the drug and the majority also includes 
porous/fluid filtration, modeled for the most part by 
Darcy equations, but also by Navier-Stokes equations 
[15] and by Darcy-Brinkman equations [14]. Simulation 
results show that the filtration field has almost a negligi-
ble effect for low-weight drugs [17,18], whilst it becomes 
significant for high-weight drugs. On the contrary, the 
contribution of RPE pumping always appear important, 
especially when the retina is the therapeutic target. The 
RPE pumping effect, included in a very limited selec-
tion of papers, is modeled as a fictitious advective field 
or through different inward/outward permeabilities of 
the RPE membrane [13,19,20]. The inclusion of the sig-
nificant clearance pathways for a certain drug adminis-
tration mode is rather varied. Choriocapillaries are often 
treated as a perfect sink [16,21] or they are modeled via 
porous jump equations [13]. Retinal blood vessels are 
only considered in [18] and, via a mixture equation ap-
proach, in [20]. Generally, the fluid filtration is assumed 
to be steady state (except for) [15] and not influenced by 
the drug transport.
Numerical Approaches and Validation 
Techniques
In table 3, we provide a comparative analysis between 
the molecules considered in each model, the mathematical 
description of the drug source, the numerical approach-
es and parameter estimates used in the considered mod-
els for drug delivery to the PSE. For the most part, low-
weight molecules are considered, with a predominance of 
the marker fluorescein on which the most part of experi-
mental data are based. Only a few papers address different 
molecules with therapeutic significance, as the anti-VEGF 
macromolecular drug ranibizumab (IgG1 Fab) in [17]. 
The drug source is represented for IV injection as a bolus 
of prescribed concentration of spherical shape [15,21] or 
time evolving shape [12] and for EP plug as a prescribed 
concentration [13] or prescribed time dependent concen-
tration [17] at the scleral boundary. In Ferreira, et al. [22], 
the drug implant is inserted in the vitreous.
The inclusion in the model of the spatial dependen-
cy leads to large systems of partial differential equations, 
whose solution with analytical techniques is unfeasible, 
if not impossible. Thus, the use of numerical methods is 
in order. Spatial discretization can be based on finite el-
ements (FEMs) [13,19] or finite volume techniques [15], 
generally implemented in commercial packages or on fi-
nite differences [18]. Different discretization schemes are 
adopted for time marching, including implicit/semi-im-
plicit finite difference schemes [13,14] and adaptive Run-
ge-Kutta schemes [20]. Three-dimensional problems give 
rise to large size systems, with a number of degrees of free-
dom ranging from about 200,000 nodes [13] to 321,000 
chamber considered in Jooybar, et al. [12] is equal 
to 4.4 ml , where as in the original model of [13], the 
volume of the vitreous is about 2.2 ml); iii) what are 
the significant clearance pathways (for example, blood 
vessels, periocular structures or lymphatic vessels) for a 
certain drug administration mode? iv) how to represent 
un-resolved structures via boundary conditions on the 
external surfaces? How to deal with internal interface/
coupling conditions? In addition, one should consider the 
fact that the PSE has unique geometrical features in each 
subject. In this respect, the common procedure consists 
in extensive literature searches and data comparisons 
so to obtain models based on a representative, average, 
geometry for a certain species (human, rabbit, mouse, 
monkey.
In table 1, we provide a comparative analysis 
between the geometrical models of the PSE adopted 
in the considered mathematical works (being for the 
totality 3D or 1D models, except for the 2D model of 
[14]. The most part of the papers considers geometrical 
parameters corresponding to the human eye, possibly 
partially derived from other species (rabbit eye, see also 
the comparative analysis carried out in [15]. Moreover, 
for the most part, these recent models consider, at least, 
vitreous and retina as separated domains. Choroid 
and sclera are sometimes lumped together in a unique 
domain, as in [16]. Anterior structures are described 
with different levels of precision, ranging from the 
“anatomically accurate” representation of [15] to the 
representation of mimicking boundary conditions of 
[17]. Interface conditions between adjacent layers l 
and m are, in their most general form, expressed by the 
permeation relation
( )lm lm int,–   
l
l l m
l
CD L P C C
n
∂
= −
∂
Dl being the diffusion coefficient in layer l with 
outward unit normal vector nl, Cl and Cm the drug 
concentrations in layers l and m, respectively, Llm the 
porous permeability of the membrane between layers 
l and m and Plm the partition coefficient keeping into 
account the affinity of the drug in the two layers. As a 
general remark, it is worth noticing that, while in [4] it 
is emphasized that fine geometric details are not needed 
to capture the salient features of drug distribution and 
only the proportions of different domains of the eye are 
considered to be important, more accurate analyses may 
need the inclusion of structures responsible of specific 
pathways (as for example the periocular space in [18] or 
the gap of Petit in [15].
Biophysical Phenomena Modeling
In table 2, we provide a comparative analysis between 
• Page 9 •
Citation: Causin P, Malgaroli F (2017) Mathematical and Numerical Methods for Modeling Drug Delivery to the 
Posterior Segment of the Eye. J Ophthalmic Res Ocular Care 1(1):4-11
SCHOLARLY  PAGES
Causin et al. J Ophthalmic Res Ocular Care 2017, 1(1):4-11
from analytical relations/correlations between different 
layers [18]. It should be observed that, whilst the actual 
value of some of these parameters will not probably af-
fect too much the results when dealing with low weight 
molecules, when considering larger/heavier molecules the 
parameter values can have a more significant impact [21].
Results
In table 4, we present the main results obtained in the 
considered mathematical models. Simulations have been 
performed to study concentration profiles in different 
conditions. Sensitivity studies have been carried out 
to address the significance of: i) certain biophysical 
mechanisms (active transport in the retina) [13,20], 
clearance rates [15]; ii) technical details in the drug 
administration (needle angle) [12], implant position 
[14]; different boundary conditions (vitreous outflow) 
[21]; implications of interspecies variability [15]; 
pathological conditions (inflammation of the retina), 
posterior vitreous detachment [22].
nodes [17] and may require the use of parallel comput-
ing (as in the simulations carried out on a quad proces-
sor in [15]. Special care must be taken when simulating 
diffusion/convection/reaction equations for drug delivery. 
Convection dominates when considering high weight/
scarcely diffusing molecules or modeling RPE pumping 
actions as a fictitious velocity field. Reaction, represent-
ing metabolic terms/degradation effects, may also become 
dominant and induce instabilities and/or unphysical neg-
ative concentration fields [4]. Best fit between the simu-
lated drug levels and experimental/in vivo data have been 
performed to assess the model validity and fit critical pa-
rameters (using for the most part fluorescein data as those 
from Palestine & Brubaker) [23] in Balachandran & Baro-
cas [13] or those from [24] in Park, et al. [21]; Gd-DTPA 
data were used in [16]. Parameters estimated from data 
fitting of fluorescein have been often used also for differ-
ent drugs/delivery routes. Diffusivity, permeability and 
RPE pumping parameters have been computed from data 
fitting [13,16,18], from analysis of TEM images [14] or 
Table 4: Validation method and main results for 3D physiological models of drug delivery to the PSE.
Reference Validation method Main results
[16] Gd-DTPA data from MRI in 
vivo and ex vivo
estimate of lumped posterior membrane (6.0 × 10-8 cm2/s) and vitreous (2.8 × 
10-6 cm2/s) diffusivity coefficient
[21] fluorescein data from in vivo 
IV injection
comparison between IV injection and implant; influence of vitreous drug 
diffusivity as a surrogate for drug molecular weight; influence of changes of the 
proportion of fluid loss by vitreous and aqueous outflows
[18] validation from GFP data 
in mouse after periocular 
injection
estimation of resistances (RPE: 9 × 105, periocular: 1.6 × 10-1 and choroid: 
3.5 × 10-3), estimation of clearance rates from fitting of experimental data; 
sensitivity analysis on resistance, clearance rates, diffusivities, void volume for 
peak concentration, peak time and total integrated concentration
[13] validation from experimental 
data for systemic 
administration
study of the influence on drug levels of RPE active pumping, episcleral losses 
and choriocapillary clearance
[15] comparison with experimental 
data in rabbit eye after 
intravitreal injection
estimate of the hydraulic resistance of the trabecular meshwork by fitting 
procedure; comparison of solutions (fluid flow and drug) in different geometries; 
parametric study of clearance from the ASE; methodology to excerpt results for 
one species (human, rabbit, monkey) from different species
[14] transient mean plasma concentration and contours of anecortave acetate for 
different blood velocities; mean concentration in the choroid as indicator of the 
drug bioavailability at the retina
[17] validation from fluoroscein 
data (IV injection, systemic)
effect of spatial inhomogeneities on episcleral drug delivery (to be compared 
with compartmental model by) [27], estimate of time duration of therapeutic 
drug levels for the igG1 Fab molecule
[19] effect drug mobility in sclera due to diffusion and permeability and of the 
partition coefficient at retina/vitreous interface and at retina/choroid interface
[12] validation from experimental 
data for systemic 
(intravenous) administration
study of the effect of injection time and needle gauge/angle; study of the effect 
of implant position/type
[20] comparison with results 
obtained from recent models 
[27,13,18]
sensitivity analysis on diffusivity, clearance rates, permeability coefficient 
for drug concentration; sensitivity analysis on filtration velocity and fictitious-
active velocity at RPE; theoretical analysis on lower and upper bound of drug 
concentration in the retina
[22] influence of vitreous liquefaction on velocity and on drug concentration in the 
retina; effect of implant position; influence on retinal drug concentration of the 
partition coefficient at vitreous/retina interface and of the rate of clearance 
at the retinal boundary; influence of intraocular pressure value on the drug 
concentration level in the retina
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papers. The parameter values obtained from experiments 
or from data fitting on the model are often very different 
and thus do not represent valid benchmarks
4. In general, experimental data are very sparse and 
significantly differ from each other. This lack of “golden 
standard experimental data” makes more difficult to dis-
pose of well assessed data for model validation purposes
5. The mathematical representation itself of the phe-
nomena (for example, representing RPE pumping effects 
by a fictitious convective field or by an altered permea-
bility) impacts on the results. However, again, there is no 
“gold standard” for carrying out a comparison.
Conclusions and Perspectives
According to the World Health Organization, in 
2010, more than 13% of the cases of blindness were the 
result of diseases of the PSE [25]. It is thus of high im-
portance to dispose of efficient and well tolerated ways 
to deliver drugs to this region. Mathematical models can 
provide tools useful to enlarge the knowledge on this 
topic, supporting and completing clinical experiments. 
In general, much space is still open when it comes to 
address therapeutically relevant drugs, especially mac-
romolecules (anti-angiogenic antibodies, oligonucle-
otides, growth factors, and trans-gene expression) [4] 
and prodrugs improving drug bio-availability) [6]. For 
these drugs, parameter estimation may need reviewing 
along with reconsideration of the significant biophysical 
With the purpose of comparison of the different 
models when computing a similar quantity, in figure 1 
we show drug peak (and mean) concentration value and 
time-to-peak in the retina and choroid. We represent the 
data where available. The results are all obtained for low-
weight molecules comparable to fluorescein. The drug is 
delivered via EP plug or EP injection. It is evident from 
the graphs a significant scattering of the results, of which 
several factors may be responsible. What appears more 
evident from our review work is that:
1. There is no general agreement on the detail level 
required for the geometrical description of the anatomical 
structures. Different choices are carried out, depending 
on the considered drug delivery route (IV injection, 
episcleral implant and even with the same approach with 
the precise location of the drug source), species (man, 
rabbit, monkey, rat) and on the intraspecies variability
2. The characteristics of the considered drug (hy-
drophilicity/lipophilicity, molecular weight and size, 
charge) can impact the choice of including or not in the 
model certain bio-physical phenomena (for example, the 
clearance routes and the permeability across membranes 
as the RPE) for a specific drug. Moreover they can also 
influence, by themselves, the geometrical detail needed 
in the description of a certain structure
3. The value of the parameters strongly influence the 
model results. This is clearly demonstrated by the results 
obtained by the sensitivity analyses performed in several 
         
Figure 1: Comparison of peak concentration (left) and time-to-peak (right) values in the retina and choroid for a fluorescein-
like drug, as obtained from different literature models (data are represented where available and upon conversion of units of 
measure). Notice the use of log scale on the y axis. Comparable values of parameters and inlet conditions are used. Values 
denoted by the symbol ‘*’ have been obtained by multiplying the values by 100 to scale drug concentration at the boundary 
(assuming a linear behavior as suggested by the results of [19]. Values from [13] have been interpreted as percentage of the 
enforced boundary concentration value, in lack of indications. 
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porous medium model. International Journal of Heat and 
Mass Transfer 55: 5665-5672.
15. Missel P (2012b) Simulating intravitreal injections in 
anatomically accurate models for rabbit, monkey, and 
human eyes. Pharmaceut Res 29: 3251-3272.
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posterior eye. Chemical Engineering Science 108: 203-212.
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Protein transport to choroid and retina following periocular 
injection: theoretical and experimental study. Ann Biomed 
Eng 35: 615-630.
19. Kotha S, Murtomaki L (2014) Virtual pharmacokinetic model 
of human eye. Math Biosci 253: 11-18.
20. Causin P, Malgaroli F (2016) Mathematical assessment 
of drug build-up in the posterior eye following transscleral 
delivery. Journal of Mathematics in Industry 6: 9.
21. Park J, Bungay PM, Lutz RJ, et al. (2005) Evaluation 
of coupled convective-diffusive transport of drugs 
administered by intravitreal injection and controlled release 
implant. J Control Release 105: 279-295.
22. Ferreira JA, de Oliveira P, da Silva PM, et al. (2017) 
Mathematics of aging: Diseases of the posterior segment 
of the eye. Computers & Mathematics with Applications 73: 
11-26.
23. Palestine AG, Brubaker RF (1981) Pharmacokinetics of 
fluorescein in the vitreous. Invest Ophthalmol Vis Sci 21: 
542-549.
24. Araie M, Maurice D (1991) The loss of fluorescein, 
fluorescein glucuronide and fluorescein isothiocyanate 
dextran from the vitreous by the anterior and retinal 
pathways. Exp Eye Res 52: 27-39.
25. Pascolini D, Mariotti S (2012) Global estimates of visual 
impairment: 2010. Br J Ophthalmol 96: 614-618.
26. Isakova K, Pralits O, Repetto R, et al. (2014) A model for 
the linear stability of the interface between aqueous humor 
and vitreous substitutes after vitreoretinal surgery. Physics 
of  Fluids 26: 124101.
27. Ninawe P, Hatziavramidis D, Parulekar SJ (2010) Delivery 
of drug macromolecules from thermally responsive gel 
implants to the posterior eye. Chemical Engineering 
Science 65: 5170-5177.
mechanisms. To cite one example, the convection field 
can become a determinant of the drug fate, and contrast/
enhance RPE pumping actions. A better understanding 
of the impact of aging/pathological conditions is neces-
sary to develop more effective therapies so that drug con-
centration is maintained within the therapeutic window 
at the target site for the desired period of time (so far 
the effect of the liquefaction of the vitreous, breakdown 
of blood retinal barrier and elevated intraocular pressure 
have been considered in Ferreira, et al.) [22]. This aspect 
should also include the effect of surgical procedures, for 
example the increased drug clearance due to vitrectomy 
[8] or the modified fluid-dynamics due to the use of vit-
reous substitutes [26].
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